Keros Therapeutics, Inc. Research and Development Expense
Keros Therapeutics, Inc. (KROS) reported Research and Development Expense of $22.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Keros Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $22.33M, a 48.67% decline year-over-year.
- Keros Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $16.10M, a 66.95% decline year-over-year.
- Keros Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $17.91M, a 60.75% decline year-over-year.
- Keros Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $19.52M, a 60.35% decline year-over-year.
- Keros Therapeutics, Inc. research and development expense for fiscal 2025 was $129.64M, a 25.33% decline from fiscal 2024.
- Keros Therapeutics, Inc. research and development expense for fiscal 2024 was $173.63M, a 28.37% increase from fiscal 2023.
- Keros Therapeutics, Inc. research and development expense for fiscal 2023 was $135.26M, a 55.00% increase from fiscal 2022.
- Keros Therapeutics, Inc. research and development expense for fiscal 2022 was $87.27M, a 58.25% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.33M 10-Q · filed 2026-08-03 | $38.43M 10-Q · filed 2026-08-03 | $56.34M derived: sum of 3 quarters · filed 2026-08-03 | $75.86M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $16.10M 10-Q · filed 2026-05-14 | $34.01M derived: sum of 2 quarters · filed 2026-05-14 | $53.53M derived: sum of 3 quarters · filed 2026-05-14 | $97.03M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $37.43M derived: sum of 2 quarters · filed 2026-03-04 | $80.93M derived: sum of 3 quarters · filed 2026-08-03 | $129.64M 10-K · filed 2026-03-04 |
| 2025-09-30 | $19.52M 10-Q · filed 2025-11-05 | $63.02M derived: sum of 2 quarters · filed 2026-08-03 | $111.73M 10-Q · filed 2025-11-05 | $157.36M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $43.50M 10-Q · filed 2026-08-03 | $92.21M 10-Q · filed 2026-08-03 | $137.84M derived: sum of 3 quarters · filed 2026-08-03 | $187.07M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $48.71M 10-Q · filed 2026-05-14 | $94.34M derived: sum of 2 quarters · filed 2026-05-14 | $143.56M derived: sum of 3 quarters · filed 2026-05-14 | $184.08M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $45.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $94.86M derived: sum of 2 quarters · filed 2026-03-04 | $135.37M derived: sum of 3 quarters · filed 2026-03-04 | $173.63M 10-K · filed 2026-03-04 |
| 2024-09-30 | $49.23M 10-Q · filed 2025-11-05 | $89.74M derived: sum of 2 quarters · filed 2025-11-05 | $128.00M 10-Q · filed 2025-11-05 | $165.49M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $40.52M 10-Q · filed 2025-08-06 | $78.77M 10-Q · filed 2025-08-06 | $116.27M derived: sum of 3 quarters · filed 2025-08-06 | $150.41M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $38.26M 10-Q · filed 2025-05-06 | $75.75M derived: sum of 2 quarters · filed 2025-05-06 | $109.89M derived: sum of 3 quarters · filed 2025-05-06 | $142.43M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $37.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $71.63M derived: sum of 2 quarters · filed 2025-02-26 | $104.17M derived: sum of 3 quarters · filed 2025-02-26 | $135.26M 10-K · filed 2025-02-26 |
| 2023-09-30 | $34.14M 10-Q · filed 2024-11-06 | $66.67M derived: sum of 2 quarters · filed 2024-11-06 | $97.77M 10-Q · filed 2024-11-06 | $122.63M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $32.53M 10-Q · filed 2024-08-07 | $63.63M 10-Q · filed 2024-08-07 | $88.49M derived: sum of 3 quarters · filed 2025-02-26 | $109.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $31.09M 10-Q · filed 2024-05-08 | $55.96M derived: sum of 2 quarters · filed 2025-02-26 | $77.00M derived: sum of 3 quarters · filed 2025-02-26 | $100.28M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $24.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $45.91M derived: sum of 2 quarters · filed 2025-02-26 | $69.19M derived: sum of 3 quarters · filed 2025-02-26 | $87.27M 10-K · filed 2025-02-26 |
| 2022-09-30 | $21.04M 10-Q · filed 2023-11-06 | $44.32M derived: sum of 2 quarters · filed 2023-11-06 | $62.40M 10-Q · filed 2023-11-06 | $81.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $23.28M 10-Q · filed 2023-08-07 | $41.36M 10-Q · filed 2023-08-07 | $60.19M derived: sum of 3 quarters · filed 2024-02-28 | $75.02M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $18.08M 10-Q · filed 2023-05-04 | $36.91M derived: sum of 2 quarters · filed 2024-02-28 | $51.74M derived: sum of 3 quarters · filed 2024-02-28 | $61.73M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $18.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $33.66M derived: sum of 2 quarters · filed 2024-02-28 | $43.65M derived: sum of 3 quarters · filed 2024-02-28 | $55.14M 10-K · filed 2024-02-28 |
| 2021-09-30 | $14.83M 10-Q · filed 2022-11-03 | $24.82M derived: sum of 2 quarters · filed 2022-11-03 | $36.31M 10-Q · filed 2022-11-03 | $45.98M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $9.98M 10-Q · filed 2022-08-04 | $21.48M 10-Q · filed 2022-08-04 | $31.15M derived: sum of 3 quarters · filed 2022-08-04 | $39.55M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $11.49M 10-Q · filed 2022-05-05 | $21.17M derived: sum of 2 quarters · filed 2022-05-05 | $29.56M derived: sum of 3 quarters · filed 2022-05-05 | $36.83M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $9.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $18.07M derived: sum of 2 quarters · filed 2022-03-09 | $25.33M derived: sum of 3 quarters · filed 2022-03-09 | $33.86M 10-K · filed 2022-03-09 |
| 2020-09-30 | $8.39M 10-Q · filed 2021-11-04 | $15.66M derived: sum of 2 quarters · filed 2021-11-04 | $24.19M 10-Q · filed 2021-11-04 | $28.35M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $7.26M 10-Q · filed 2021-08-05 | $15.79M 10-Q · filed 2021-08-05 | $19.95M derived: sum of 3 quarters · filed 2021-08-05 | $23.81M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $8.53M 10-Q · filed 2021-05-06 | $12.69M derived: sum of 2 quarters · filed 2021-05-06 | $16.54M derived: sum of 3 quarters · filed 2021-05-06 | $21.04M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $8.02M derived: sum of 2 quarters · filed 2021-03-25 | $12.51M derived: sum of 3 quarters · filed 2021-03-25 | $17.38M 10-K · filed 2021-03-25 |
| 2019-09-30 | $3.85M 10-Q · filed 2020-11-10 | $8.35M derived: sum of 2 quarters · filed 2020-11-10 | $13.22M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $4.50M 10-Q · filed 2020-08-13 | $9.36M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $4.87M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |